SAN DIEGO--(BUSINESS WIRE)--
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its ImmunoPulse DNA-based immunotherapy to treat solid tumors, will present an update of data from their Phase 2 melanoma study at the American Society of Clinical Oncology’s 50th Annual Meeting, taking place May 30-June 3, 2014, at McCormick Place in Chicago, Illinois. Additional details will be made available on or after May 14, 2014, via the ASCO webpage: http://www.asco.org
“It is an honor to be selected to present in a Poster Highlights Session at this year’s conference,” said Punit Dhillon, President and CEO of OncoSec Medical. “We salute ASCO’s efforts to advance oncology research and look forward to sharing data from our Phase 2 melanoma study with conference attendees and participants.”
Lead author, Dr. Adil Daud, will present an abstract titled, “Systemic anti-tumor effect and clinical response in a phase 2 trial of intratumoral electroporation of plasmid interleukin-12 in patients with advanced melanoma” (ASCO Abstract #9025), which highlights unreleased data from the company’s Phase 2 study investigating the use of ImmunoPulse in patients with metastatic melanoma. The abstract will be part of the Poster Highlights Session: Melanoma and Skin Cancers, taking place June 2, 2014. For more information, please refer to the ASCO iPlanner: https://iplanner.asco.org/AM2014
Said Robert Pierce, M.D., Chief Medical Officer, “We are excited by the opportunity to present data from our Phase 2 study, which is nearing completion. Our presentation will be one of those highlighting the therapeutic potential of intralesional therapy and the power of modulating the immune system in the treatment of cancer.”
ASCO 2014 will bring together over 25,000 oncology professionals from a wide range of specialties to explore this year’s theme – “Science and Society”. Attendees will have access to cutting-edge scientific presentations and comprehensive educational content that reflect ASCO’s dedication to providing the highest-quality resources in education, policy, the pioneering of clinical research, and the advancement of care for patients with cancer.
About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing its ImmunoPulse immunotherapy to treat solid tumors. OncoSec Medical's core technology leverages a proprietary electroporation platform to enhance the local delivery and uptake of IL-12 and other DNA-based immune-modulating agents. Clinical studies of ImmunoPulse have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers, as well as the potential to initiate a systemic immune response without the systemic toxicities associated with other treatments. OncoSec's clinical programs currently include three Phase 2 trials targeting metastatic melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma (http://clinicaltrials.gov/ct2/results?term=oncosec&Search=Search). As the company continues to evaluate ImmunoPulse in these indications, it is also investigating additional indications and combination therapeutic approaches. For more information, please visit www.oncosec.com.
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward-looking statements.” Forward-looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties, which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition, and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical’s filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. OncoSec Medical disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
- Health Care Industry
- Disease & Medical Conditions
Veronica Vallejo, CFO, 855-662-6732